Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We ...

Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

ADAR1 Capital Management challenges Keros Therapeutics on capital allocation and board decisions. Read more here.

Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a ...

Things were looking up for the UL Ragin’ Cajuns when they scored five runs in the second inning during the third game of ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: ...

USM (38-13, 21-6 Sun Belt) swept its third, consecutive Sun Belt series, running its conference win streak to 10 consecutive ...

Warren Buffett says that if he were to start again, he’d look for old-fashioned value stocks. Stephen Wright thinks there’s an unusual one on offer. The post Why I’m considering considering breaking ...

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is ...